The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer

Current Oncology

Volumn 8, Issue 2, 2001, Pages 50-59

  Logan, D ^a   Laurie, S ^a   Markman, B R ^a   McNeil, M ^a   Vincent, M ^a   Evans, W K ^a   Alam, Y ^a   Brundage, M ^a   Campling, B ^a   Darling, G ^a   Dixon, P ^a   Feld, R ^a   Findlay, B ^a   Goss, G ^a   Graham, I ^a   Gregg, R ^a   Iscoe, N ^a   Kocha, W ^a   Kolin, A ^a   Kotalik, J ^a   Lochrin, C ^a   Lopez, P ^a   Malthaner, R ^a   Maziak, D ^a   McIvor, A ^a   Miller, J ^a   Okawara, G ^a   Rusthoven, J ^a   Shepherd, F ^a   Stewart, D ^a   Chung Ung, Y ^a   Urschel, J ^a   Wenckebach, G ^a   Yu, E ^a   more..

^a CANCER CARE ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IFOSFAMIDE; NAVELBINE; PLATINUM;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034747955     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation
2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
4. Docetaxel benefits lung cancer symptoms and quality of life in a randomized phase III study of non-small cell lung cancer patients previously treated with platinum-based therapy
5. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
6. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial
7. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
8. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature
9. Phase II trials of Taxotere in patients with non-small cell lung cancer
10. 2 in platinum-pretreated advanced non-small cell lung cancer
11. Single agent docetaxel and primary prophylactic lenograstim in pretreated patients with advanced non small cell lung cancer (NSCLC): A multicenter phase II study
12. Early phase II of docetaxel in second line of advanced non small cell lung cancer (NSCLC): Preliminary results
13. 2/3 weeks in a second line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
14. Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy
15. Weekly docetaxel as second line therapy of advanced non small cell lung cancer (NSCLC): A preliminary feasibility report
16. Single-agent docetaxel in patients with refrac tory non-small-cell lung cancer